secwatch.observer — SEC 8-K summary
======================================

Issuer:     UroGen Pharma Ltd. (URGN)
CIK:        0001668243
Form:       8-K
Filed at:   2024-03-04T23:59:59+00:00
Accession:  0001193125-24-056770
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

UroGen presents at TD Cowen conference; no material updates provided
--------------------------------------------------------------------

- Presentation furnished as Exhibit 99.1 for TD Cowen 44th Annual Health Care Conference on March 4, 2024.
- Title slide states: 'Developing Innovative Medicines to Treat Urothelial Cancers'.
- No specific financial, clinical, or guidance data included in the filing or exhibit excerpt.
- Filing is procedural Regulation FD disclosure; no new material events reported.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1668243/000119312524056770/0001193125-24-056770-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1668243/000119312524056770/d743593d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-056770

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer